Cover Image
市場調查報告書

Debiopharm International S.A. :產品平台分析

Debiopharm International S.A. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 315710
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
Debiopharm International S.A. :產品平台分析 Debiopharm International S.A. - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 54 Pages
簡介

Debiopharm International S.A. 是致力於開發腫瘤、免疫、感染疾病等治療藥的生物製藥公司。此外也提供臨床實驗各階段的藥物輸送、設計、製造、品質保證等服務。

本報告提供Debiopharm International S.A.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Debiopharm International S.A.的基本資料

  • Debiopharm International S.A.概要
  • 主要資訊
  • 企業資料

Debiopharm International S.A. :R&D概要

  • 主要的治療範圍

Debiopharm International S.A. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Debiopharm International S.A. :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Debiopharm International S.A. :開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Debiopharm International S.A. :藥物簡介

  • triptorelin pamoate
  • alisporivir
  • Debio-1452
  • AT-406
  • Debio-0932
  • Debio-1347
  • Debio-1450
  • Debio-0617B
  • Debio-0719
  • Debio-0929
  • Debio-0930B
  • Debio-1036
  • Debio-0826
  • Debio-1142
  • Debio-1348
  • Debio-1449
  • Debio-1453
  • Debio-1454

Debiopharm International S.A. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Debiopharm International S.A. :最近的開發平台趨勢

Debiopharm International S.A. :暫停中的計劃

Debiopharm International S.A. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07192CDB

Summary

Global Markets Direct's, 'Debiopharm International S.A. - Product Pipeline Review - 2015', provides an overview of the Debiopharm International S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Debiopharm International S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Debiopharm International S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Debiopharm International S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Debiopharm International S.A.'s pipeline products

Reasons to buy

  • Evaluate Debiopharm International S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Debiopharm International S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Debiopharm International S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Debiopharm International S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Debiopharm International S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Debiopharm International S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Debiopharm International S.A. Snapshot
    • Debiopharm International S.A. Overview
    • Key Information
    • Key Facts
  • Debiopharm International S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Debiopharm International S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Debiopharm International S.A. - Pipeline Products Glance
    • Debiopharm International S.A. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Debiopharm International S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Debiopharm International S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Debiopharm International S.A. - Drug Profiles
    • triptorelin pamoate PR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisporivir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1450
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1452
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-406
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1347
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-0617B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-0719
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-0929
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-0930B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-0826
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1449
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1453
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Debio-1454
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Debiopharm International S.A. - Pipeline Analysis
    • Debiopharm International S.A. - Pipeline Products by Target
    • Debiopharm International S.A. - Pipeline Products by Route of Administration
    • Debiopharm International S.A. - Pipeline Products by Molecule Type
    • Debiopharm International S.A. - Pipeline Products by Mechanism of Action
  • Debiopharm International S.A. - Recent Pipeline Updates
  • Debiopharm International S.A. - Dormant Projects
  • Debiopharm International S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CUDC-305
  • Debiopharm International S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Debiopharm International S.A., Key Information
  • Debiopharm International S.A., Key Facts
  • Debiopharm International S.A. - Pipeline by Indication, 2015
  • Debiopharm International S.A. - Pipeline by Stage of Development, 2015
  • Debiopharm International S.A. - Monotherapy Products in Pipeline, 2015
  • Debiopharm International S.A. - Partnered Products in Pipeline, 2015
  • Debiopharm International S.A. - Partnered Products/ Combination Treatment Modalities, 2015
  • Debiopharm International S.A. - Phase III, 2015
  • Debiopharm International S.A. - Phase II, 2015
  • Debiopharm International S.A. - Phase I, 2015
  • Debiopharm International S.A. - Preclinical, 2015
  • Debiopharm International S.A. - Discovery, 2015
  • Debiopharm International S.A. - Pipeline by Target, 2015
  • Debiopharm International S.A. - Pipeline by Route of Administration, 2015
  • Debiopharm International S.A. - Pipeline by Molecule Type, 2015
  • Debiopharm International S.A. - Pipeline Products by Mechanism of Action, 2015
  • Debiopharm International S.A. - Recent Pipeline Updates, 2015
  • Debiopharm International S.A. - Dormant Developmental Projects,2015
  • Debiopharm International S.A. - Discontinued Pipeline Products, 2015
  • Debiopharm International S.A., Subsidiaries

List of Figures

  • Debiopharm International S.A. - Pipeline by Top 10 Indication, 2015
  • Debiopharm International S.A. - Pipeline by Stage of Development, 2015
  • Debiopharm International S.A. - Monotherapy Products in Pipeline, 2015
  • Debiopharm International S.A. - Partnered Products in Pipeline, 2015
  • Debiopharm International S.A. - Pipeline by Top 10 Target, 2015
  • Debiopharm International S.A. - Pipeline by Top 10 Route of Administration, 2015
  • Debiopharm International S.A. - Pipeline by Top 10 Molecule Type, 2015
  • Debiopharm International S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top